The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
The RESTORE Study
Open accessAbstract
OBJECTIVE: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). DESIGN: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. PARTICIPANTS: We included 345 patients aged ≥18 years, with type 1 or 2 diabetes mellitus and visual impairment due to DME. METHODS: Patients were randomized to ranibizumab + sham laser (n = 116), ranibizumab + laser (n = 118), or sham injections + laser (n = 111). Ranibizumab/sham was given for 3 months then pro re nata (PRN); laser/sham laser was given at baseline then PRN (patients had scheduled monthly visits). MAIN OUTCOME MEASURES: Mean average change in BCVA from baseline to month 1 through 12 and safety. RESULTS: Ranibizumab alone and combined with laser were superior to laser monotherapy in improving mean average change in BCVA letter score from baseline to month 1 through 12 (+6.1 and +5.9 vs +0.8; both P<0.0001). At month 12, a significantly greater proportion of patients had a BCVA letter score ≥15 and BCVA letter score level >73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P<0.001). Health-related quality of life, assessed through National Eye Institute Visual Function Questionnaire (NEI VFQ-25), improved significantly from baseline with ranibizumab alone and combined with laser (P<0.05 for composite score and vision-related subscales) versus laser. Patients received ∼7 (mean) ranibizumab/sham injections over 12 months. No endophthalmitis cases occurred. Increased intraocular pressure was reported for 1 patient each in the ranibizumab arms. Ranibizumab monotherapy or combined with laser was not associated with an increased risk of cardiovascular or cerebrovascular events in this study. CONCLUSIONS: Ranibizumab monotherapy and combined with laser provided superior visual acuity gain over standard laser in patients with visual impairment due to DME. Visual acuity gains were associated with significant gains in VFQ-25 scores. At 1 year, no differences were detected between the ranibizumab and ranibizumab + laser arms. Ranibizumab monotherapy and combined with laser had a safety profile in DME similar to that in age-related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,428
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0493 · Cited by 720
Self-citationThe 14-year incidence of visual loss in a diabetic population,
Moss, S. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)96025-0 · Cited by 672
(2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.015 · Cited by 548
Treatment Techniques and Clinical Guidelines for Photocoagulation of Diabetic Macular Edema
(1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33527-4 · Cited by 544
Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
Nguyen, Q. D., Shah, S. M., Khwaja, A. A., Channa, R., Hatef, E., Do, D. V., Boyer, D., Heier, J. S., Abraham, P., Thach, A. B., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.08.016 · Cited by 532
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Boyer, D. S., Yoon, Y. H., Belfort, R., Bandello, F., Maturi, R. K., Augustin, A. J., Li, X.-Y., Cui, H., Hashad, Y., & Whitcup, S. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.024 · Cited by 1,122
Self-citationWong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Diabetic Retinopathy: A Position Statement by the American Diabetes Association
Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017) · Diabetes Care · doi:10.2337/dc16-2641 · Cited by 940
Brown, D. M., Nguyen, Q. D., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Schlottmann, P. G., Rundle, A. C., Zhang, J., Rubio, R. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.02.034 · Cited by 830
Intravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
Self-citationKlaassen, I., Van Noorden, C. J. F., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 722
Self-citationDiabetic Retinopathy Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.025 · Cited by 717
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 703
Self-citationStandards of medical care for type 2 diabetes in China 2019
Jia, W., Weng, J., Zhu, D., Ji, L., Lu, J., Zhou, Z., Zou, D., Guo, L., Ji, Q., Chen, L., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3158 · Cited by 700
Intravitreal Aflibercept for Diabetic Macular Edema
Brown, D. M., Schmidt-Erfurth, U., Do, D. V., Holz, F. G., Boyer, D. S., Midena, E., Heier, J. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.017 · Cited by 623
Self-citationTreatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.047 · Cited by 562
Diabetic retinopathy - ocular complications of diabetes mellitus
Nentwich, M. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.489 · Cited by 553
Automated Analysis of Retinal Images for Detection of Referable Diabetic Retinopathy
Abràmoff, M. D., Folk, J. C., Han, D. P., Walker, J. D., Williams, D. F., Russell, S. R., Massin, P., Cochener, B., Gain, P., Tang, L., et al. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.1743 · Cited by 463
Self-citation11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
Current Epidemiology of Diabetic Retinopathy and Diabetic Macular Edema
Ding, J., & Wong, T. Y. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0283-6 · Cited by 439
Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy
Lin, K., Hsih, W., Lin, Y., Wen, C., & Chang, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13480 · Cited by 446
Prevalence of and Risk Factors for Diabetic Macular Edema in the United States
Varma, R., Bressler, N. M., Doan, Q. V., Gleeson, M., Danese, M., Bower, J. K., Selvin, E., Dolan, C., Fine, J., Colman, S., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.2854 · Cited by 423
Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory
Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., Lopez-Galvez, M., Navarro-Gil, R., & Verges, R. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2156273 · Cited by 404
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Rajendram, R., Fraser-Bell, S., Kaines, A., Michaelides, M., Hamilton, R. D., Esposti, S. D., Peto, T., Egan, C., Bunce, C., Leslie, R. D., et al. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2012.393 · Cited by 389
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., Berliner, A. J., Gao, B., Zeitz, O., Ruckert, R., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.010 · Cited by 385
Self-citationChiu, S. J., Allingham, M. J., Mettu, P. S., Cousins, S. W., Izatt, J. A., & Farsiu, S. (2015) · Biomedical Optics Express · doi:10.1364/boe.6.001172 · Cited by 377
Ocular complications of diabetes mellitus
Sayin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.92 · Cited by 358
Petrillo, J., Cano, S. J., McLeod, L. D., & Coon, C. D. (2015) · Value in Health · doi:10.1016/j.jval.2014.10.005 · Cited by 355
Gonzalez, V. H., Campbell, J., Holekamp, N. M., Kiss, S., Loewenstein, A., Augustin, A. J., Ma, J., Ho, A. C., Patel, V., Whitcup, S. M., et al. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.09.012 · Cited by 352
Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema
Schmidt-Erfurth, U., Lang, G. E., Holz, F. G., Schlingemann, R. O., Lanzetta, P., Massin, P., Gerstner, O., Bouazza, A. S., Shen, H., Osborne, A., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.041 · Cited by 325
Self-citationWolf, S., Balciuniene, V. J., Laganovska, G., Menchini, U., Ohno-Matsui, K., Sharma, T., Wong, T. Y., Silva, R., Pilz, S., & Gekkieva, M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.023 · Cited by 317
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy
Capitão, M., & Soares, R. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25575 · Cited by 312
10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 302
Gillies, M. C., Lim, L. L., Campain, A., Quin, G. J., Salem, W., Li, J., Goodwin, S., Aroney, C., McAllister, I. L., & Fraser-Bell, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.002 · Cited by 301
Baker, C. W., Glassman, A. R., Beaulieu, W. T., Antoszyk, A. N., Browning, D. J., Chalam, K. V., Grover, S., Jampol, L. M., Jhaveri, C. D., Melia, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.5790 · Cited by 299
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297
Self-citationDiabetic retinopathy: pathogenesis, clinical grading, management and future developments
Heng, L. Z., Comyn, O., Peto, T., Tadros, C., Ng, E., Sivaprasad, S., & Hykin, P. G. (2013) · Diabetic Medicine · doi:10.1111/dme.12089 · Cited by 285
Sahni, J., Patel, S. S., Dugel, P. U., Khanani, A. M., Jhaveri, C. D., Wykoff, C. C., Hershberger, V. S., Pauly-Evers, M., Sadikhov, S., Szczesny, P., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.023 · Cited by 285
Gupta, N., Mansoor, S., Sharma, A., Sapkal, A., Sheth, J., Falatoonzadeh, P., Kuppermann, B., & Kenney, M. (2013) · The Open Ophthalmology Journal · doi:10.2174/1874364101307010004 · Cited by 285
Kiziltoprak, H., Tekin, K., Inanc, M., & Goker, Y. S. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i3.140 · Cited by 282
Zur, D., Iglicki, M., Busch, C., Invernizzi, A., Mariussi, M., Loewenstein, A., Busch, C., Cebeci, Z., Chhablani, J. K., Chaikitmongkol, V., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.031 · Cited by 271
Virgili, G., Menchini, F., Casazza, G., Hogg, R., Das, R. R., Wang, X., & Michelessi, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008081.pub3 · Cited by 265
Takahashi, H., Tampo, H., Arai, Y., Inoue, Y., & Kawashima, H. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179790 · Cited by 257
12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s012 · Cited by 177
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s012 · Cited by 169
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176
Sivaprasad, S., & Oyetunde, S. (2016) · Clinical Ophthalmology · doi:10.2147/opth.s100168 · Cited by 134
Fenwick, E. K., Xie, J., Ratcliffe, J., Pesudovs, K., Finger, R. P., Wong, T. Y., & Lamoureux, E. L. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8992 · Cited by 101
Contemporary retinal imaging techniques in diabetic retinopathy: a review
Cole, E. D., Novais, E. A., Louzada, R. N., & Waheed, N. K. (2016) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12711 · Cited by 91
on behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative, Looker, H. C., Nyangoma, S. O., Cromie, D. T., Olson, J. A., Leese, G. P., Philip, S., Black, M. W., Doig, J., Lee, N., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2928-7 · Cited by 80
Leese, G. P., Stratton, I. M., Land, M., Bachmann, M. O., Jones, C., Scanlon, P., Looker, H. C., & Ferguson, B. (2015) · Diabetes Care · doi:10.2337/dc14-1778 · Cited by 50
Bioactive lipids and pathological retinal angiogenesis
Elmasry, K., Ibrahim, A. S., Abdulmoneim, S., & Al‐Shabrawey, M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14507 · Cited by 39
Metadata
- Authors
- Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., & Weichselberger, A.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 118
- Issue
- 4
- Pages
- 615-625
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2161279821
- Cited by
- 1,326
- References
- 19
- FWCI
- 84.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.